Short communication: Fluoroquinolone susceptibility of Staphylococcus aureus strains isolated from caprine clinical mastitis in southeast Spain

被引：5

作者：

Marin, P. ^{[1
]}

Escudero, E. ^{[1
]}

Fernandez-Varon, E. ^{[1
]}

Carceles, C. M. ^{[1
]}

Corrales, J. C. ^{[2
]}

Gomez-Martin, A. ^{[2
]}

Martinez, I. ^{[1
]}

机构：

[1] Univ Murcia, Dept Pharmacol, E-30071 Murcia, Spain

[2] Univ Murcia, Dept Anim Hlth, Fac Vet Med, E-30071 Murcia, Spain

来源：

JOURNAL OF DAIRY SCIENCE | 2010年 / 93卷 / 11期

关键词：

Staphylococcus aureus; fluoroquinolone; mastitis; goat milk; PHARMACOKINETIC-PHARMACODYNAMIC INTEGRATION; BOVINE; ORBIFLOXACIN; DANOFLOXACIN; OVINE; RABBITS; CATTLE; HERDS;

D O I：

10.3168/jds.2010-3345

中图分类号：

S8 [畜牧、动物医学、狩猎、蚕、蜂];

学科分类号：

0905 ;

摘要：

The antibiotic susceptibility of 32 strains of Staphylococcus aureus isolated from the mastitic milk of dairy goats was evaluated. The antibiotics tested were 3 fluoroquinolones that have been developed especially for use in veterinary medicine: danofloxacin; marbofloxacin, and orbifloxacin. Minimum inhibitory concentration (MIC) tests were performed according to the microdilution broth method. The MIC90 (concentration at which 90% inhibition is achieved) values obtained were 0.5, 1, and 1 mg/L for danofloxacin, marbofloxacin, and orbifloxacin, respectively. Danofloxacin was the most active fluoroquinolone tested against Staph. aureus strains isolated from milk; however; specific testing is required before using these drugs as therapy for the control of clinical mammary infections in goats.

引用

页码：5243 / 5245

页数：3

共 27 条

[1] Characterization of Staphylococcus aureus isolates from buffalo, bovine, ovine, and caprine milk samples collected in Rio de Janeiro State, Brazil
Aires-de-Sousa, Marta
Parente, Carlos E. S. R.
Vieira-da-Motta, Olney
Bonna, Isabel C. F.
Silva, Denise A.
de Lencastre, Herminia
[J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2007, 73 (12) : 3845 - 3849
[2] Fluoroquinolones in animal health
Brown, SA
[J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1996, 19 (01) : 1 - 14
[3] *CLSI, 2008, M37A3 CLSI NCCLS
[4] *CLSI, 2009, M07A8 CLSI NCCLS
[5] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
Craig, WA
[J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
[6] Coagulase gene polymorphism of Staphylococcus aureus isolated from goat mastitis in Brazilian dairy herds
da Silva, ER
Boechat, JUD
da Silva, N
[J]. LETTERS IN APPLIED MICROBIOLOGY, 2006, 42 (01) : 30 - 34
[7] Effect of enrofloxacin treatment on plasma endotoxin during bovine Escherichia coli mastitis
Dosogne, H
Meyer, E
Sturk, A
van Loon, J
Massart-Leën, AM
Burvenich, C
[J]. INFLAMMATION RESEARCH, 2002, 51 (04) : 201 - 205
[8] Pharmacokinetic-pharmacodynamic integration of danofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits
Fernandez-Varon, E.
Marin, P.
Escudero, E.
Vancraeynest, D.
Carceles, C. M.
[J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2007, 30 (01) : 18 - 24
[9] In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections
Ganière, JP
Médaille, C
Etoré, F
[J]. RESEARCH IN VETERINARY SCIENCE, 2004, 77 (01) : 67 - 71
[10] CLINICAL PHARMACOKINETICS OF PARENTERALLY ADMINISTERED DANOFLOXACIN IN CATTLE
GILES, CJ
MAGONIGLE, RA
GRIMSHAW, WTR
TANNER, AC
RISK, JE
LYNCH, MJ
RICE, JR
[J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1991, 14 (04) : 400 - 410

← 1 2 3 →